DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FAMCICLOVIR

Clinical Trials for Famciclovir

Subscribe to access the full database, or request a copy of the full page.
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00098046	Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection	Completed	Novartis	Phase 3	2005-07-01	Varicella zoster virus causes chickenpox in children and shingles in adults. Chickenpox is usually a self-limiting illness characterized by fever and a rash. Serious complications can include secondary bacterial infections, pneumonia, and encephalitis. Anti-viral treatment is not a standard of care in immunocompetent children, but is recommended whenever a risk of complication exists. This study will evaluate the safety and blood levels of a new formulation of famciclovir in children 1-12 years of age.
NCT00098059	Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection	Completed	Novartis Pharmaceuticals	Phase 3	2005-02-01	This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir (12.5 mg/kg) to assess pharmacokinetics (PK) and safety. In Part B, patients will receive multiple doses of famciclovir alone or with concomitant oral anti-herpes therapy to assess safety and tolerability. Part B will start only after PK data from Part A had been analyzed.
NCT00129818	A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding	Completed	Novartis	Phase 4	2004-07-01	The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.
NCT00171990	Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes	Completed	Novartis	Phase 3	2003-01-01	This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States.
NCT00219310	RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir	Completed	Novartis	Phase 4	2003-06-01	This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.
NCT00248144	A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis	Completed	Novartis	Phase 4	2003-10-01	The study is designed to assess the efficacy and safety of patient-initiated therapy with famciclovir 1500 mg o.d. or 750 mg b.i.d. for one day treatment in adult men and women with recurrent herpes labialis
NCT00297011	Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis	Completed	GlaxoSmithKline	Phase 2	2004-09-01	A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary